Score Breakdown
Below average.
ImmunityBio has a genuinely promising immunotherapy platform with ANKTIVA showing strong clinical data and accelerating commercial adoption (700% revenue growth). However, the investment case is severely impaired by: (1) explicit going concern doubt with only 9.5 months of cash runway, (2) ~35% annual dilution destroying shareholder value, (3) $505M in related-party debt creating circular founder dependency, (4) $324.6M RIPA liability with punitive true-up provisions, (5) $214M+ arbitration liability, (6) negative stockholders' equity, and (7) an $8.5B market cap on $113M TTM revenue (75x P/S) with deeply negative margins. The stock trades as if profitability and scale are assured, but the path there requires massive additional capital that will come at shareholders' expense. Even in a bull case where ANKTIVA becomes a blockbuster, current shareholders are likely to be diluted 50-70% before the company reaches cash flow breakeven. The 121% short interest reflects these structural concerns. This is a science story priced for perfection on a capital structure designed for destruction of minority shareholder value.
Negative cash flow. Can't value it.
Major red flags in SEC filings.
Shares melting fast.
No data.
Clock is ticking.
Heavy bearish bets.
Incompetent.
🐻 Why Bears Hate It
The bear thesis centers on a persistent net loss ($351.4 million in 2025) and a high cash burn rate that threatens further dilution. Bears point to an 'overheated' valuation with a Price-to-Sales ratio exceeding 90x and potential geopolitical disruptions to the commercial launch in the Middle East. Additionally, the company remains heavily dependent on the sole global supplier of BCG (Merck) for its combination therapies, posing a significant supply-chain risk (Source: GuruFocus, Intellectia.AI, March 2026).
🔍 What's In The SEC Filings
The company is technically insolvent and reliant on the founder's personal wealth to meet a $3.7 billion accumulated deficit while facing aggressive dilutive pressure and multi-hundred-million dollar legal claims.
Explicit Auditor Warning of Substantial Doubt
“substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support.”
The company has an accumulated deficit of $3.7 billion and negative operating cash flow of $304.9 million, leaving it entirely dependent on the Founder's 'intent' to provide loans.
High-Interest Revenue Interest Liability (RIPA)
“If the aggregate Revenue Interest Payments made to Oberland as of the Test Date are less than the aggregate amount of Cumulative Purchaser Payments... then the company must make the True-Up Payment.”
The RIPA is a $324.6 million liability where failure to hit sales targets triggers a massive 'True-Up' payment, effectively acting as high-cost debt secured by substantially all assets.
Significant Milestone/CVR Arbitration
“SRS’s arbitration demand seeks relief in the form of payment, in the amount of approximately $164.2 million plus interest exceeding $50.0 million.”
Former Altor shareholders are suing for over $214 million, alleging the company failed to use 'commercially reasonable efforts' to hit a regulatory milestone by the deadline.
Extreme Customer and AR Concentration
“As of December 31, 2025, the company’s 3PL Agent made up 100% of its trade accounts receivable, net balance.”
96% of total gross revenue comes from just four customers, and the entire AR balance is held by a single third-party logistics agent, creating massive counterparty risk.
Circularity of Debt and Equity with Founder
“the September 2023 financing transactions between the company and Dr. Soon-Shiong and his affiliates were not fair to the company... resulting in an artificially low conversion price.”
The company repeatedly converts debt held by the founder into equity, often timed during stock price volatility, as evidenced by the dismissed but notable Carlson derivative action.
Intrinsic value is severely impaired by the $500M stockholders' deficit. Any valuation should apply a massive liquidity discount and assume further 15-20% dilution annually to maintain operations.
A change in auditors occurred between 2024 and 2025 (EY to Deloitte). Management's reliance on 'non-clinical IND enabling studies' to extend maturity dates of related-party notes suggests a lack of arm's-length financial discipline.
At the current burn rate, this company will need to raise money or die.